Strengthen capacity of the South African Government’s Department of Health to provide quality and sustainable clinical care for HIV-infected patients with complicated HIV and HIV/TB treatment management, including 2nd and 3rd line and other antiretr | CDC RFA GH13 133503CONT16

Opportunity Information: Apply for CDC RFA GH13 133503CONT16

This grant opportunity is a continuation cooperative agreement from the U.S. Centers for Disease Control and Prevention (CDC) under PEPFAR that focuses on strengthening the South African Department of Health's ability to deliver high-quality, sustainable clinical care for people living with HIV who have complicated treatment needs. The central aim is to improve clinical management for patients who are failing first-line therapy or who require more advanced regimens, including second-line and third-line antiretroviral therapy (ART), as well as patients dealing with HIV and tuberculosis (HIV/TB) co-infection where treatment decisions and follow-up are more complex. In practical terms, the opportunity is about building and reinforcing government health system capacity so that complicated HIV cases are diagnosed accurately, managed consistently according to evidence-based guidelines, and supported over time within routine public-sector services rather than relying on short-term or parallel programs.

The award is explicitly restricted to continuation funding for organizations that were already funded under the earlier CDC announcement CDC-RFA-GH13-1335. That means it is not an open competition for new applicants; it is intended to extend or continue an existing body of work with the same implementing partners previously selected by CDC. The funding instrument is a cooperative agreement, which generally indicates substantial involvement from CDC in implementation oversight, technical guidance, performance monitoring, and alignment with broader PEPFAR and national program priorities. The opportunity is categorized under health (CFDA 93.067) and was created on September 30, 2015, with an original closing date of November 30, 2015, reflecting the administrative window for the continuation action.

Programmatically, the work supported by this continuation funding is aimed at improving the quality and sustainability of clinical services for patients with advanced or complicated HIV disease, including those with drug resistance, treatment failure, adherence challenges, co-morbidities, and HIV/TB co-management needs. Typical capacity-strengthening efforts under a project of this type often include supporting the Department of Health to refine and implement clinical guidelines for second- and third-line ART, expand access to appropriate diagnostic and monitoring tools (such as viral load monitoring and resistance-related clinical decision pathways), strengthen referral systems for complex cases, and build clinical mentoring and supervision structures so that clinicians can manage complicated patients effectively at different levels of care. It also commonly involves strengthening data systems and case monitoring so that treatment outcomes, regimen switches, and retention in care are tracked reliably, which is essential for managing second- and third-line cohorts and ensuring patients are not lost during transitions in therapy.

A key feature of the opportunity is its emphasis on sustainability within the South African public health system. Rather than creating stand-alone services, the intention is to bolster government-led clinical care delivery so that specialized HIV and HIV/TB treatment management can be provided at scale, with consistent quality, and maintained over time. Because this is supported under PEPFAR, the continuation award also implicitly aligns with broader PEPFAR goals such as improving treatment outcomes, reducing HIV-related morbidity and mortality, and strengthening national health systems so that complex HIV care is integrated into routine services.

Administrative details included in the source data indicate an award ceiling listed as 0 and the expected awards field left blank, which commonly happens in continuation postings where funding levels and award counts are determined by prior-year agreements, budget approvals, and performance rather than a new competitive cap. Eligible applicants are listed as "Others," but the narrative makes clear that only existing grantees from the predecessor funding opportunity are eligible for this continuation. In short, this is a CDC/PEPFAR continuation cooperative agreement designed to keep an established partner effort moving forward, with the specific purpose of strengthening South Africa's capacity to manage complicated HIV and HIV/TB cases, especially those requiring second- and third-line ART, through improved clinical systems, workforce capacity, and sustainable government-led service delivery.

• The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Strengthen capacity of the South African Government’s Department of Health to provide quality and sustainable clinical care for HIV-infected patients with complicated HIV and HIV/TB treatment management, including 2nd and 3rd line and other antiretr" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.067.
• This funding opportunity was created on 2015-09-30.
• Applicants must submit their applications by 2015-11-30. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Others.

Apply for CDC RFA GH13 133503CONT16

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: